此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

用于慢性神经性疼痛的脑岛神经调节

2026年9月30日 更新者:Jeff Elias, MD、University of Virginia

岛叶神经调节治疗难治性慢性神经性疼痛的阶段性综合研究

This study will comprehensively investigate the insula as a brain target for neuromodulation to treat chronic neuropathic pain.

研究概览

地位

招聘中

详细说明

In the first stage, 12 subjects with refractory neuropathic pain will be enrolled to an inpatient clinical trial for insular brain mapping with acute stimulation and neurophysiological brain monitoring. Electrodes for stimulation and recording will be implanted stereotactically to the insular cortex. 'Responders' to trial stimulation and the optimal region of the insula for pain relief will be identified during this inpatient stage.

'Responder' subjects who have positive analgesic effects from acute insular stimulation during the first stage will continue to the second stage. The second stage, clinical trial is conducted outpatient and will test chronic deep brain stimulation of the insula. The study design is randomized, sham-stimulation-controlled, double-blinded, and cross-over where subjects receive both active and sham stimulation. Furthermore, neurophysiological biomarkers of pain will be investigated by studying changes in neural activity.

研究类型

介入性

注册 (估计的)

12

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Virginia
      • Charlottesville、Virginia、美国、22903
        • 招聘中
        • University of Virginia
        • 首席研究员:
          • Jeff Elias, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Men and women, between 18 and 80 years, inclusive

  2. Subjects who are able and willing to give consent and able to attend all study visits

  3. The pain is:

    • chronic with ≥6 month duration
    • severe is defined as: 'average' NPRS score of ≥ 5 out of 10 at current visit and the subject reports having a similar level of pain for at least the past two months
    • disabling and has resulted in an inability to work or perform ADLs in the home
    • medication-refractory to adequate trials of at least 3 prescription medications (including at least one current or past opioid) commonly used for symptomatic relief of pain. An adequate medication trial is defined as a therapeutic dose of each medication without sufficient effect.
    • treatment-resistant and cannot be treated or has failed procedures including interventional therapies with injections, spinal neuromodulation with medication infusion or stimulation, and neurosurgical ablation surgery.
  4. The pain is neuropathic or predominantly neuropathic if mixed components.

    • Subject suffering from a pure neuropathic pain syndrome will be included if the pain has resulted from a specific injury including trauma, ischemia, hemorrhage, infection, tumor or iatrogenic to either the peripheral (nerve, spinal root, plexus, cranial nerve) or to the central nervous system (spinal cord or brain) Etiologies include:
    • Poststroke pain
    • Thalamic pain
    • Spinal cord injury
    • Brachial plexus injury or limb avulsion
    • Peripheral nerve injury or painful neuropathy
    • Postherpetic neuralgia, Tolosa Hunt syndrome, or cavernous sinus syndromes
    • Trigeminal neuropathic pain (not trigeminal neuralgia)
  5. Insula region must be apparent on MRI so that direct targeting can be performed for SEEG and DBS electrode placement.

  6. Able to communicate and report sensations during all stimulation testing

  7. Stable prescribed doses of all symptomatic pain medications for 30 days prior to study entry and for the duration of the study.

  8. Inclusion and exclusion criteria have been agreed upon by the principal investigator and the pain psychologist, both of whom have interviewed, examined and if appropriate provided psychotherapeutic intervention to the subject.

Exclusion Criteria:

  1. Idiopathic pain syndromes will be excluded. Examples include:

    1. Fibromyalgia syndrome
    2. temporomandibular joint disorders
    3. irritable bowel syndrome
    4. chronic headaches
    5. interstitial cystitis
    6. chronic pelvic pain
    7. whiplash-associated disorders
  2. Subjects deemed poor candidates by a multidisciplinary team of pain clinicians including specialists in neurosurgery, pain management, and pain psychology:

    1. Significant clinician concern(s) about reliability of subject-reported information, such as subject in active process of seeking disability for neuropathic pain
    2. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-V as manifested by one (or more) of the following occurring within a 12 month period: Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household). Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use)
    3. Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct)
    4. Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights).
    5. Suspected dementia based on neuropsychological screening or Mini Mental State Exam (MMSE) Score < 25
  3. Subjects with active psychiatric illness will be excluded. For the purpose of this study, active psychiatric illness includes:

    1. History of significant psychiatric disorder (e.g., comorbid schizophrenia, bipolar disorder, suicidal ideation/attempts) that could interfere with interpretation of study endpoints.
    2. Exhibiting current suicide ideation and/or a history of suicide attempt within past 2 years
    3. been hospitalized for the treatment of a psychiatric illness within the past 2 years
    4. received transcranial magnetic stimulation for depression treatment
    5. received electroconvulsive therapy for depression
    6. any presence or history of psychosis
  4. Subjects with unstable cardiac status including:

    1. Unstable angina pectoris on medication
    2. Subjects with documented myocardial infarction within six months of protocol entry
    3. Significant congestive heart failure defined with ejection fraction < 40
    4. Subjects with unstable ventricular arrhythmias
    5. Subjects with atrial arrhythmias that are not rate-controlled
  5. Severe hypertension (diastolic BP > 100 on medication)

  6. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.

  7. On medications that increases the bleeding risk, based on the published guidelines41 which are currently recognized by the American Society of Regional Anesthesia and Pain Medicine, American Academy of Pain Medicine and the North American Neuromodulation Society; specifically:

    1. Aspirin or another antiplatelet medication (clopidogrel, prasugrel, ticlopidine, abiciximab) for the last 7 days prior to treatment.
    2. Oral, subcutaneous or intravenous anticoagulant medications, such as oral vitamin K inhibitors for the last 7 days, non-vitamin K inhibitor oral anticoagulant (dabigatran, apixaban, rivaroxaban) for the last 72 hours.
    3. Intravenous or subcutaneous heparin-derived compounds for the last 48 hours.
  8. Individuals who are not able or willing to tolerate prolonged hospitalization with continuous video EEG monitoring

  9. Subjects participating or have participated in another clinical trial to investigate or treat chronic pain in the last 30 days

  10. Subjects with risk factors for intraoperative or postoperative bleeding from a documented coagulopathy or if their serum coagulation studies (platelet count, PT, PTT, and INR) exceed the institutional laboratory limits.

  11. Subjects with brain tumors or any significant intracranial mass.

  12. Subjects with a history of seizure

  13. Any illness that in the investigator's opinion preclude participation in this study

  14. Pregnancy or lactation

  15. Subjects with a true allergy to opioid medications which would preclude PET imaging

  16. Legal incapacity or limited legal capacity

  17. Subjects with a deep brain stimulation implant

  18. History of hemorrhagic stroke or cerebrovascular event within the past year of treatment exhibiting incomplete resolution

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
假比较器:Control

Subjects who respond favorably to test/trial stimulation of the insula will be implanted with DBS devices. In an outpatient clinical trial, each subject will receive 3 months of active stimulation and 3 months of sham stimulation. The assignment for stimulation will be randomized and blinded to the subject and to the outcome assessors.

During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.

Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation.

其他名称:
  • 深部脑刺激
有源比较器:DBS of the insula

Subjects who respond favorably to test/trial stimulation of the insula will be implanted with DBS devices. In an outpatient clinical trial, each subject will receive 3 months of active stimulation and 3 months of sham stimulation. The assignment for stimulation will be randomized and blinded to the subject and to the outcome assessors.

During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.

Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation.

其他名称:
  • 深部脑刺激

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Adverse events
大体时间:Entire study period from enrollment through 6 months post DBS implantation

Adverse event reporting will be collected throughout the study period. This will include neurological assessments by the study team postoperatively using the NIH Stroke Scale, MR imaging of implanted electrodes, comprehensive assessment of mood and cognition by a licensed psychologist, and vigilance for suicide with the asQ Screening Tool.

Entire study period from enrollment through 6 months post DBS implantation
Pain intensity
大体时间:Baseline, 3 months post DBS stimulation, 3 months post sham stimulation

The primary efficacy outcome measure compares the change in pain intensity, as rated by the blinded subjects using the Numeric Pain Rating Scale (NPRS), between bilateral DBS of the insula and sham stimulation. The NPRS is an 11 point scale where 0 represents "no pain" and 10 represents the "worst possible pain." Clinical pain severity will be assessed daily in the home environment with a 7-day Ecological Momentary Assessment (NPRS rating) aggregated across days. The analysis will focus on DBS-ON Week 12 data relative to the DBS-OFF (Sham) Week 12 data, controlling for Baseline data.

Baseline, 3 months post DBS stimulation, 3 months post sham stimulation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jeff Elias, MD、University of Virginia

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年11月1日

初级完成 (估计的)

2028年7月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2022年5月26日

首先提交符合 QC 标准的

2022年5月31日

首次发布 (实际的)

2022年6月3日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅